NEKTAR THERAPEUTICS cotiza a 37.92 USD y tiene una capitalización bursátil de $1.3B. En los últimos 12 meses ha facturado $55M con un margen de flujo de caja libre del -377.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory d…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-1.21 | — | $-1.78 |
| Estimado | $-2.07 | $-2.04 | $-2.04 | $-1.48 |
| Sorpresa | — | +40.7% | — | -20.3% |
| Métrica | NKTR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.0% | +43.0% |
| Operating Margin | -253.7% | -38.6% | -215.0% |
| Net Margin | -297.1% | -33.6% | -263.5% |
| FCF Margin | -377.8% | -13.9% | -364.0% |
| ROE | -182.7% | -40.4% | -142.3% |
| ROA | -58.5% | -32.0% | -26.5% |
| Current Ratio | 4.97 | 2.84 | +2.13 |
| Debt / Equity | — | 0.28 | — |